FILING ANALYSIS · MONDAY, NOVEMBER 16

AYTU BIOPHARMA, INC AYTU — 8-K: Results of Operations and Financial Condition

positive

The company announced a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. to be acquired for $2.70 per share in cash, representing total consideration of approximately $56 million, and reported fiscal 2027 first quarter operational and financial results with net revenue increasing 6.9% to $14.8 million.

The filing

8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+